Quigley Pharma Inc. Granted Patent For Prophylactic And Anti-Transmissivity Uses Of An Anti-Microbial Composition

DOYLESTOWN, Pa., Feb. 12 /PRNewswire-FirstCall/ -- The Quigley Corporation today announced that it has been granted its seventh patent, Patent No. US 7,166,435B2 for its application "Compositions and Methods for Reducing the Transmissivity of Illnesses." This patent was developed by Quigley Pharma, www.QuigleyPharma.com, the Company's wholly owned subsidiary. This patent will provide additional protection to an existing composition patent (number 6,592,896), which the Company received in July 2003 and will support on-going investigations and potential commercialization opportunities. The Company will be continuing its studies to test the effects of the referenced compound against avian flu and human influenza.

Among the most noteworthy of 30 claims cited in the patent are "A method of reducing the transmissivity of a virus, comprising the step of administering to a mammal or a bird that has been exposed to an illness caused by a virus or has contracted an illness caused by a virus" AND "A method for the prophylactic use of a composition to reduce one or more of the severity of a viral illness, severity of symptoms of the viral illness, and incidence of symptoms of the viral illness, comprising the step of administering to a mammal or a bird that has been or will be exposed to the viral illness."

The Company cited a combination of 13 in-vitro and in-vivo experiments illustrating the virustatic, virucidal and prophylactic capacity of the compound as well as product dose and delivery concepts to support the patent claims. The experimental examples, which were carried out by Retroscreen Virology, Ltd., included evaluations of the compound's effects on various viruses, including but not limited to, human influenza types A & B, avian flu H5N1, SARs and herpes viruses. The possible application forms included, but were not limited to, medical feeds, lozenges, nasal sprays and throat sprays.

"This intellectual property will support our continued efforts in the development of therapeutic agents, QR-441(a) against avian influenza and QR-435 against human influenza. The potential for a naturally derived formulation that may inhibit an influenza virus' capacity to be transmitted is an exciting concept," stated Dr. Richard Rosenbloom, COO of Quigley Pharma.

About the QR Compounds:

QR-435 is a potential prescription nasal spray indicated for the prevention and treatment of Influenza type A and B.

QR-441(a) is being investigated in several dose forms including food and water additives and spray application as a prophylactic treatment against avian flu for the commercial poultry industry. The compound is being researched under the FDA INAD guidelines for veterinary drug development.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will allow the aforementioned Compounds to be tested and/or marketed in humans and/or animals. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has four (4) wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 kpineman@schwartz.comcarlh@schwartz.com

The Quigley Corporation

CONTACT: Media - Karen Pineman, kpineman@schwartz.com, or InvestorRelations - Carl Hymans, carlh@schwartz.com, both of G.S. Schwartz & Co.,+1-212-725-4500

Back to news